Physician profile
Mary C Ball
NPI 1801888938
$710.43
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $201 · 2021: $428 · 2022: $81.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $190.20 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $155.97 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $83.68 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $65.26 | 2021 | |
| Amgen INC. | $51.88 | 2020-2021 | |
| Glaxosmithkline, LLC. | $25.03 | 2020 | |
| Indivior INC. | $20.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.05 | 2021 | |
| Alkermes, INC. | $17.19 | 2020 | |
| Hologic Sales and Service, LLC | $14.47 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.42 | 2021 | |
| Novo Nordisk INC | $14.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.90 | 2021 | |
| Lilly USA, LLC | $12.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.12 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.